Single Nucleotide Polymorphisms Genotyping Market | 2032

Report Description

Single Nucleotide Polymorphisms Genotyping Market Outlook 2032

The global single nucleotide polymorphisms genotyping market size was USD 25.5 Billion in 2023 and is likely to reach USD 152.7 Billion by 2032, expanding at a CAGR of 22% during 2024–2032. The market growth is driven by the miniaturization of equipment and increased multiplexing capacity, with SNP technologies being extensively used for the detection of various human diseases.

SNP genotyping is a powerful technique that identifies and analyzes variations in single DNA building blocks (nucleotides) within the human genetic code. These variations, known as single nucleotide polymorphisms (SNPs), play a crucial role in understanding individual differences in health, disease susceptibility, and response to medications. Researchers and healthcare professionals are able to gain valuable insights into identifying genetic markers associated with specific diseases, personalized medicine, drug development, and population genetics by analyzing and comparing SNPs across individuals.

The global SNP genotyping market is expanding due to the growing advancements in technology, as new methods are faster, cheaper, and more accurate than existing ones. Rising awareness of personalized medicine is increasing, as individuals become interested in understanding their genetic predisposition to diseases. Moreover, the investment in drug discovery boosts the market, as SNP genotyping is heavily used in drug development to identify new drug targets and optimize treatment efficacy.

High-density SNP genotyping is gaining traction, which has the ability to generate 500,000 genotypes on each subject. Affymetrix, which sells the 500K Human Mapping Arrays (HMA500K), and Illumina, which provides HumanHap650Y BeadChip that contains over 650,000 SNP, are the major producers of high-density SNP genotyping.

Important aspects of SNP genotyping include technology platforms, such as PCR-based techniques, microarrays, and next-generation sequencing (NGS). Each platform has its advantages and limitations, with NGS offering high throughput and resolution. SNP genotyping is rapidly revolutionizing to identification of health and disease, paving the way for personalized medicine and optimized healthcare interventions. The market is fueled by technological advancements, data analysis breakthroughs, and growing awareness of the potential of SNP genotyping.

Get Free Sample Report

Impact of Artificial Intelligence (AI) on the Single Nucleotide Polymorphisms Genotyping Market

The emergence of artificial intelligence is projected to boost the single nucleotide polymorphisms genotyping market. AI plays a crucial role in the analysis and interpretation of genomic datasets, particularly in SNP genotyping. Machine learning algorithms identify patterns and potential genetic markers, accelerating research and aiding in the interpretation of complex genomic information.

AI-powered tools improve the accuracy and efficiency of SNP genotyping processes, reducing errors and streamlining the research and clinical testing pipeline. AI also unravels complex genetic relationships, leading to a better understanding of the genetic basis of conditions and targeted therapies. It also accelerates drug discovery by identifying potential drug targets based on SNP data, leading to targeted pharmaceuticals. AI also facilitates the integration of SNP genotyping data with other omics data, making genotyping processes user-friendly and accessible.

Single Nucleotide Polymorphisms Genotyping Market Dynamics

Get Free Sample Report

Major Drivers

Rising incidence of deadly illnesses, such as diabetes, cancer, and chronic diseases, is driving the global market. The diagnosis of cancer and chronic diseases are diagnosed precisely with SNP genotyping. The growing need for genetic analysis in animal and plant feedstock is also boosting the market. Furthermore, the existence of both public and commercial funding initiatives in the field of genetics is anticipated to boost the market during the forecast period.

Existing Restraints

Single nucleotide polymorphism genotyping technologies face several challenges, including high costs, data analysis complexity, ethical and regulatory issues, lack of standardization and interoperability, limited genomic diversity in databases, and market saturation. These factors limit adoption of SNP genotyping, particularly among small research facilities or organizations with budget constraints. Additionally, limited genomic diversity in databases also restrains the market.

Emerging Opportunities

­Emerging technologies such as CRISPR-Cas9 for editing and nanopore sequencing for rapid analysis promise great affordability and speed, which creates immense opportunities in the market. Integration of SNP genotyping with AI-powered data analysis unlocks a deep understanding of complex genetic variations, propelling personalized medicine forward. Non-invasive DNA collection methods such as saliva tests increase accessibility, leading to broad population studies. Global initiatives such as the 1000 Genomes Project are generating invaluable data for understanding human diversity and disease susceptibility. The SNP genotyping market is poised to revolutionize the healthcare industry with its transformative potential by tackling ethical considerations and data privacy concerns.

Scope of the Single Nucleotide Polymorphisms Genotyping Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Single Nucleotide Polymorphisms Genotyping Market Segment Insights

Technology Segment Analysis

Based on technology, the single nucleotide polymorphisms genotyping market is segmented into SNP genechips and microarrays, TaqMan assay, SNP genotyping based on pyrosequencing, SN plex based on applied biosystems, Sequenom MasARRAY, MALDI TOF, RFLP, SSCP, ARMS, and others. The SNP genechips and microarrays segment held a major share of the market in 2023. The segment growth is attributed to the rising demand for diagnostic research, pharmacogenomics, and animal breeding owing to the technological advancements in sequencing, which results in reduced cost of sequencing. Furthermore, the increasing requirement to sequence a large number of samples at a single time is boosting the segment.

The TaqMan assay segment is expected to expand at a significant CAGR during the forecast period, as it is a multiplexed assay that is being utilized heavily in animal breeding, animal diagnostics, and research applications for genetic diseases in animals, as well as in the agriculture sector for dairy products, cash crops, and food crops. The TaqMan assay increases the sensitivity of the quantitative PCR, hence driving the market. 

Get Free Sample Report

Application Segment Analysis

On the basis of application, the single nucleotide polymorphisms genotyping market is divided into animal genetics, plant improvements, diagnostic research, aquacultures, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and animal livestock and breeding.

The pharmaceuticals and pharmacogenomics segment held a large market share in 2022 due to the rising demand for personalized medicines. The pharmaceutical industry leverages SNPs to understand the responses of individuals to drugs and personalized treatments. The growing research on genetic factors influencing drug efficacy and adverse events and increasing investments in pharmacogenomics research by pharmaceutical companies drive the segment.

The agricultural biotechnology segment is expected to register considerable growth in the coming years. The agricultural field utilizes SNPs for various applications, such as improving crop yields and disease resistance, selecting livestock with desired traits, and optimizing animal and plant breeding programs. The growing focus on food security and sustainable agricultural practice, coupled with advancements in gene editing technologies, fuels this segment.

Get Free Sample Report

End-user Segment Analysis

On the basis of end-user, the global single nucleotide polymorphisms genotyping market is segmented into pharmacogenomics and diagnostic fields. The pharmacogenomics segment dominated the market in terms of revenue generation in 2023 owing to the various applications of SNP in pharmacogenomics, such as enhancing drug safety, reducing adverse drug reactions (ADRs), and enhancing drug discovery for human diseases and efficacy trials. Moreover, the efficiency of pharmacogenomics in checking the drug response is propelling the segment.

Regional Outlook

In terms of region, the global single nucleotide polymorphisms genotyping market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023 due to its advanced healthcare infrastructure and the presence of key market players in this region. Furthermore, heightened awareness and high acceptance of SNP genotyping in the region are boosting the market. Moreover, rising advanced technologies, strong R&D facilities, and government policies supporting the early detection, screening, and treatment of deadly diseases are propelling the market in North America.

The market in Asia Pacific is projected to expand at a significant pace in the coming years owing to the large population and strong requirement for a batch diagnostic method. Furthermore, increasing R&D activities for drug discovery in this region is driving the market in the region.

Get Free Sample Report